Nutriband Inc Cash Flow Conversion Efficiency
Nutriband Inc cash flow conversion efficiency. Based on the latest financial reports, Nutriband Inc (NTRB) has a cash flow conversion efficiency ratio of -0.110x as of July 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-585.00K) by net assets ($5.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nutriband Inc (2016–2026)
Cash flow conversion efficiency of Nutriband Inc from 2016 to 2026. This chart illustrates how Nutriband Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NTRB stock price and chart for real-time trading data and today's change.
Nutriband Inc Cash Flow Conversion Ratio Explained
Nutriband Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nutriband Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nutriband Inc ranked by their cash flow conversion efficiency. Also see NTRB stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VivoPower PLC
NASDAQ:VIVO
|
N/A |
|
Europap Tezol Kagit Sanayi Ve Ticaret AS
IS:TEZOL
|
0.105x |
|
Pinetree Capital Ltd
TO:PNP
|
-0.082x |
|
NICE Total Cash Management Co. Ltd
KQ:063570
|
0.149x |
|
ZUE SA
WAR:ZUE
|
0.137x |
|
Kamat Hotels (I) Limited
NSE:KAMATHOTEL
|
0.085x |
|
Sumeeko Industries Co Ltd
TWO:2066
|
0.070x |
|
Formosa Electronic Industries
TWO:8171
|
-0.075x |
Annual Cash Flow Conversion Efficiency for Nutriband Inc (2016–2026)
The table below shows the annual cash flow conversion efficiency of Nutriband Inc from 2016 to 2026. Review Nutriband Inc (NTRB) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-01-31 | $6.68 Million | $-5.13 Million | -0.769x | -6.81% |
| 2025-01-31 | $6.43 Million | $-4.63 Million | -0.720x | -31.36% |
| 2024-01-31 | $6.44 Million | $-3.53 Million | -0.548x | -57.24% |
| 2023-01-31 | $8.57 Million | $-2.99 Million | -0.348x | -47.10% |
| 2022-01-31 | $11.86 Million | $-2.81 Million | -0.237x | -467.13% |
| 2021-01-31 | $7.11 Million | $-297.06K | -0.042x | +99.18% |
| 2020-01-31 | $175.43K | $-894.47K | -5.099x | -1009.06% |
| 2019-01-31 | $2.40 Million | $-1.11 Million | -0.460x | +39.84% |
| 2018-01-31 | $121.51K | $-92.86K | -0.764x | +88.06% |
| 2017-01-31 | $23.11K | $-147.92K | -6.401x | -149.63% |
| 2016-01-31 | $-11.47K | $-147.92K | 12.897x | -- |
About Nutriband Inc
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company… Read more